Changes in Kidney Function Do Not Differ between Healthy Adults Consuming Higher-Compared with Lower- or Normal-Protein Diets: A Systematic Review and Meta-Analysis

Michaela C Devries,1 Arjun Sithamparapillai,2 K Scott Brimble,3 Laura Banfield,4 Robert W Morton,2 and Stuart M Phillips2

1Department of Kinesiology, Faculty of Applied Health Sciences, University of Waterloo, Waterloo, Canada; 2Department of Kinesiology, Faculty of Science; 3Department of Medicine, Division of Nephrology; and 4Health Sciences Library, Faculty of Health Sciences, McMaster University, Hamilton, Canada

Abstract

Background: Higher-protein (HP) diets are advocated for several reasons, including mitigation of sarcopenia, but their effects on kidney function are unclear.

Objective: This meta-analysis was conducted to determine the effect of HP intakes on kidney function in healthy adults.

Methods: We conducted a systematic review and meta-analysis of trials comparing HP (≥1.5 g/kg body weight or ≥20% energy intake or ≥100 g protein/d) with normal- or lower-protein (NLP; ≥5% less energy intake from protein/d compared with HP group) intakes on kidney function. Medline and EMBASE databases were searched. Randomized controlled trials comparing the effects of HP with NLP (>4 d duration) intakes on glomerular filtration rate (GFR) in adults without kidney disease were included.

Results: A total of 2144 abstracts were reviewed, with 40 articles selected for full-text review; 28 of these were analyzed and included data from 1358 participants. Data were analyzed using random-effects meta-analysis (RevMan 5; The Cochrane Collaboration), meta-regression (STATA; StataCorp), and dose-response analysis (Prism; GraphPad). Analyses were conducted using postintervention (post) GFR and the change in GFR from preintervention to post. The post-only comparison showed a trivial effect for GFR to be higher after HP intakes [standardized mean difference (SMD): 0.19; 95% CI: 0.07, 0.31; P = 0.002]. The change in GFR did not differ between interventions (SMD: 0.11; 95% CI: −0.05, 0.27; P = 0.16). There was a linear relation between protein intake and GFR in the post-only comparison (r = 0.332, P = 0.03), but not between protein intake and the change in GFR (r = 0.184, P = 0.33). The main limitation of the current analysis is the unclear risk of selection bias of the included trials.

Conclusions: Postintervention GFR comparisons indicate that HP diets result in higher GFRs; however, when changes in GFR were compared, dietary protein had no effect. Our analysis indicates that HP intakes do not adversely influence kidney function on GFR in healthy adults.

Keywords: glomerular filtration rate, GFR, renal failure, chronic kidney disease, protein, meta-analysis

Introduction

Higher-protein (HP) intakes [>1.0–1.2 g · kg body weight (BW)−1 · d−1] promote greater muscle hypertrophy during periods of resistance training (1), and not only increase the absolute amount of weight lost (2) but preserve lean body mass during weight loss (2, 3). HP intake (compared with the RDA) has also been advocated for older persons to preserve skeletal muscle mass loss due to sarcopenia (4, 5). Hypothesized mechanisms underpinning greater exercise-induced changes in lean mass with protein supplementation in resistance training include greater and more regular stimulation of muscle protein synthesis (6), and the same may be true in the setting of weight loss (2, 3). HP intake during weight loss may also increase satiety, resulting in lower daily energy intake (7); and protein ingestion has an increased thermic effect, resulting in greater daily energy expenditure (8). Given the prevalence of overweight, obesity, and global aging, the preservation of muscle mass via consumption of an HP diet may be advantageous.

Despite the proposed benefits of consuming an HP diet to preserve muscle mass or promote muscle hypertrophy, HP diets are often discouraged because of potential negative effects on kidney function, particularly glomerular filtration rate...
Aiming for 0.8 g protein diet, even in those with CKD; and recent guidelines recommend no benefit, and potential harm, in consuming a lower-protein mortality (11). More recent investigations have, however, found no benefit, and potential harm, in consuming a lower-protein diet, even in those with CKD; and recent guidelines recommend aiming for 0.8 g protein · kg BW\(^{-1}\) · d\(^{-1}\) and not consuming >1.3 g · kg BW\(^{-1}\) · d\(^{-1}\) (12). However, it is on the basis of the aforementioned hypothesis that some argue that increased protein intake in healthy individuals without CKD will lead to kidney damage. Such a hypothesis persists despite no evident link between increased protein intake and a causal role in kidney damage in healthy individuals having been established. In fact, a causal role for protein in the decline in kidney function is dismissed in guidelines for protein intake (13).

Schwingshackl and Hoffmann (14) conducted a systematic review and meta-analysis of the effects of HP compared with normal- or lower-protein (NLP) intake on kidney function in people without CKD. The analysis included acute studies (as short as 1 d in duration) and found that HP diets induced an increase in GFR, serum urea, and urinary calcium excretion compared with NLP diets. However, in their analysis, the authors compared only postintervention (post) GFR between groups rather than the absolute change in GFR in response to the dietary treatments. Given that GFR may have differed between groups at study entry, conducting an analysis only on post values may have influenced the findings of the meta-analysis. Furthermore, no attempt was made to examine whether there is a dose-response effect of protein intake on GFR. The purpose of the current systematic review, meta-analysis, and meta-regression was to examine whether GFR increases to a greater extent after an HP diet as determined by change from baseline as compared with an NLP diet in individuals without CKD.

### Methods

#### Search strategy and study identification

A systematic search of published studies was conducted in Medline and EMBASE from inception inclusive to 3 April 2017. Search terms included a combination of keywords and subject headings as appropriate for dietary proteins, amino acids (essential and nonessential), protein-restricted diet, vegetarian diet, fish protein, vegetable protein, milk, yolk, eggs, soy protein, protein metabolism, nitrogen metabolism, high protein diet, low protein diet, glomerular filtration rate, inulin clearance, kidney circulation, renal circulation, kidney function, kidney circulation, proteinuria, albuminuria, creatinine, inulin, and hemoglobinuria (Supplemental Methods 1). Searches were limited to clinical trials by applying the maximizing sensitivity McMaster Health Information Research Unit filters for Medline and EMBASE (15, 16). Searches were further limited to humans by excluding studies that used mice and rats because limiting the search to humans was insufficient. Last, searches were limited to the English language and duplicates were removed. MCD and AS reviewed the search strategies, abstracts, and full-text articles and abstracted all data. We also reviewed the reference lists of previous systematic reviews and included relevant trials.

#### Study inclusion and exclusion criteria

Studies were included if they were randomized controlled trials (RCTs) that studied the effect of HP intake with moderate (greater than the RDA but lower than the HP intake) or lower-protein (RDA or less) intake on GFR in adults aged ≥18 y. Studies were included if they enrolled participants who were healthy, obese, had type 2 diabetes, and/or had hypertension. Studies were excluded if they enrolled participants with type 1 diabetes, CKD, or any other pre-existing indicators of kidney impairment (i.e., proteinuria, previous stone formation) or if subjects had recently undergone any surgical procedures. To be included, protein had to be consumed orally but could be in any form (food, powder, oral pill). Furthermore, the HP diet had to meet ≥1 of the following criteria: 1) ≥1.5 g protein · kg BW\(^{-1}\) · d\(^{-1}\), 2) ≥20% of total caloric intake coming from protein, or 3) ≥100 g protein/d. In addition, the NLP diet had to provide ≥5% less, as a percentage of total daily energy intake, protein than the HP diet (17). To avoid acute transient changes in kidney function, which we viewed as irrelevant for ascertaining the impact on long-term kidney function, studies were excluded if the intervention was <3 d or if the study investigated the acute effects of only one meal or protein load. All of the following calculations or estimations of GFR were permitted: creatinine clearance, isotope clearance, inulin clearance, inorthalame clearance, ioehxol clearance, sinistrin clearance, Cockett-Gault calculations, modification of diet in renal disease calculations, and chronic kidney disease epidemiology collaboration calculations. Finally, studies were excluded if they were only provided in abstract form.

#### Data extraction and data syntheses

Study characteristics and data were extracted to RevMan 5 (Review Manager, version 5.3; The Cochrane Collaboration, 2015). Where necessary and possible, all subject baseline data and outcome measures were converted to the same units. If data were missing, then the authors were contacted or values were extracted from published tables and graphs. When data were missing and values could not be inferred from the publication, these studies were excluded from the respective comparison or analysis.

For the post-only analysis, post GFR values and SDs from parallel-group trials were directly input into RevMan. To account for within-participant differences in the crossover trials in the post-only analysis we used the generic inverse-variance method in RevMan. To input data using this method we first calculated the standardized mean difference (SMD) between the post values and the pooled SD for the HP and NLP groups.

In the preintervention (pre/post) change analysis, only 4 studies used a crossover design and not enough data were available to account for within-participant differences; thus, data from crossover studies were included as if they were parallel-group analyses, and mean differences and change SDs (SD\(_A\)) were calculated and input. Mean differences for each group within a study (HP and NLP) were calculated as follows:

\[
\text{Mean difference} = \text{Mean post} - \text{Mean pre} \quad (1)
\]

SD\(_A\) was input from reported values where possible. When SD\(_A\) was not reported and raw data were not available, SD\(_A\) was calculated

Author disclosures: MCD, AS, KSB, LB, and RWM, no conflicts of interest. SMP reports having received research funding, travel support, and honoraria from the US National Dairy Council, Dairy Farmers of Canada, and the US National Beef Cattlemen’s Association.

Supplemental Methods 1 and Supplemental Table 1 are available from the “Supplementary data” link in the online posting of the article and from the same link in the online table of contents at https://academic.oup.com/jn/.

Address correspondence to SMP (e-mail: phillis@mcmaster.ca).

Abbreviations used: BW, body weight; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; GFR, glomerular filtration rate; GRADE, Grades of Recommendation, Assessment, Development, and Evaluation; HP, higher-protein; NLP, normal- or lower-protein; post, postintervention; pre, preintervention; RCT, randomized controlled trial; SD, change in SD; SMD, standardized mean difference.
where corr(pre, post) is the correlation between pre- and post-values across participants. This was calculated from studies that reported SDΔ and/or raw data for a given outcome and applied across trials as detailed in the Cochrane Handbooks for Systematic Reviews of Interventions (18). If a study reported mean differences and SDs for 2 different populations (due to age or another demographic characteristic), then they were treated as separate studies in the data analysis.

Meta-analyses. Because of differences in the presentation of data between studies (i.e., reporting GFR after the intervention only compared with reporting GFR both before and after the intervention), 2 meta-analyses were performed on GFR, the outcome of interest. Not all studies reported GFR values before starting the dietary intervention, and thus one meta-analysis evaluated the difference in GFR between groups after the dietary intervention (post-only). However, given the variability in GFR within the population, it may be more appropriate to assess the effect of a dietary intervention on kidney function by comparing the change in GFR induced by the dietary interventions. Thus, where possible, the other meta-analysis compared the change in GFR from baseline induced by each diet (pre/post change). In the post-only analysis, we conducted 3 separate analyses, one on the crossover studies using generic inverse-variance data, one on the parallel-group studies using continuous data, and one on the combined data from crossover and parallel-group trials using generic inverse-variance data. In addition, because a lack of a washout period could influence the overall findings of a study, we conducted a sensitivity analysis where we removed the crossover trials that did not include a washout period between arms. Furthermore, because crossover trials were included as if they were parallel-group trials in the pre/post change analysis, we conducted a sensitivity analysis by including only the parallel-group studies to ensure that the inclusion of crossover studies did not influence the overall results. Effect sizes were categorized as trivial, small, moderate, large, very large, nearly perfect, or perfect (SMD = 0.0, 0.2, 0.6, 1.2, 2.0, 4.0, or infinity) as defined by Hopkins (19), which are based on Cohen’s thresholds but align better with Cohen’s thresholds for correlation coefficients (20).

Heterogeneity and risk-of-bias assessment. All of the extracted data were assessed for heterogeneity and publication bias. Heterogeneity was tested by using chi-square and I² tests. Significance was set as P < 0.05 for the chi-square test. I² values of 30–60%, 50–90%, and 75–100% were taken to indicate moderate, substantial, and considerable heterogeneity, respectively. In the presence of heterogeneity, random-effects meta-analysis was used. Publication bias was assessed with visual inspection of funnel plots. Last, when funnel plot asymmetry existed in the presence of heterogeneity, then the results from both fixed- and random-effects models were compared to verify that the results of the random-effects meta-analysis were not greater than those of the fixed-effects model (21).

Risk of bias was assessed by using domain-based evaluation as described by the Cochrane Collaboration (18). Studies were not included if they reported >2 high-risk domains. Furthermore, sensitivity analyses were performed to determine if the inclusion of trials with >3 unclear risk domains or 2 high-risk domains influenced the results.

Assessment of the certainty in the evidence. We conducted an evaluation of the certainty in the evidence using the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach. Certainty in the evidence means to what extent the estimates in treatment effect are correct or close to the truth (22). In GRADE, when assessing certainty,RCTs start as high; however, serious or very serious issues across 5 domains may reduce the certainty of: 1) risk of bias, 2) inconsistency, 3) imprecision, 4) indirectness, and 5) publication bias (23). We conducted this assessment for all included outcomes across studies.

Subgroup analyses. Given the potential for a carryover effect from the previous treatment with crossover trials, subgroup analysis was conducted to determine whether trial type influenced the overall outcome. We also examined whether measuring GFR after the intervention only, compared with determining the change induced by the intervention, influenced the overall results. To do so we compared the effect size from the post-only comparison with that of the pre/post change comparison in only those studies that reported GFR before and after the dietary intervention. Because different populations and interventions were used, subgroup analysis was also conducted to determine the effects of an HP diet on GFR: during energy balance or energy restriction, in participants with type 2 diabetes, on the basis of intervention length, and whether carbohydrate or fat intake was manipulated. Given the potential for changes in protein intake to influence serum creatinine concentrations (24, 25), subgroup analysis was performed on the basis of measurement type (i.e., true measurements of clearance compared with estimations of GFR from serum creatinine concentrations). Given that various methods with different units were used to assess glomerular function, SMDs were analyzed with the use of fixed- or random-effects meta-analyses. Forest plots were generated for each outcome to show study-specific effect sizes and their corresponding 95% CIs as well as the overall pooled effect. Means ± SDs are reported.

Meta-regression. We used meta-regressions to probe several other variables that may influence GFR. Five covariates were chosen a priori to be included in the meta-regression. Continuous variables were differences in protein intake between groups (grams per kilogram of BW per day), trial length (weeks), and age. Categorical variables were whether or not participants had type 2 diabetes and whether the study was conducted under conditions of energy restriction or energy balance. The covariates were meta-regressed individually and together in random-effects meta-regression model using Stata (Stata Statistical Software, release 12, 2011; StataCorp LP). The random-effects meta-regression used residual restricted maximum likelihood to measure between-study variance (r2) with a Knapp-Hartung modification as recommended (26). Additional covariates were identified and individually analyzed post hoc to further examine the unexplained variance of the effect of HP intake on GFR. Continuous variables were as follows: weight, energy intake, difference in protein intake as a percentage of total energy intake, and difference in protein intake (grams per day). Whether the study design was a parallel-group or crossover RCT was included as a categorical variable.

Dose-response analysis. To determine if there was a dose-response effect of protein consumption on GFR we conducted a linear regression analysis on the effect of daily protein intake on the change in GFR and the post-only GFR response. Linear and biphasic regressions were performed using GraphPad Prism (version 6; GraphPad Software, Inc.) to determine models of best fit as previously described (27, 28). Significance was set at P < 0.05, and the breakpoint analysis is presented as means (95% CIs).

Results

Study and subject characteristics

The Medline search yielded a total of 1326 articles and the EMBASE search yielded a total of 818 articles after all duplicates were removed within each database. A total of 2144 abstracts were examined, and 40 studies were selected for full-text review on the basis of the inclusion and exclusion criteria. In addition, reviewing the reference lists of previous systematic reviews and included trials identified a further 7 articles. Five studies were excluded because they were either only published
in abstract form or the full text could not be obtained. Fourteen studies were excluded upon review of the full text, which yielded a remaining total of 28 studies that were included in the analyses. The study inclusion and exclusion process was conducted by 2 investigators (MCD and AS) and is shown in Figure 1.

Articles reporting on 28 trials from 2144 articles were eligible for inclusion on the basis of the inclusion and exclusion criteria. The detailed progression of study inclusion and exclusion is shown in Figure 1. The included studies were published between 1975 and 2016. Fourteen of the studies were parallel-group RCTs and 14 were crossover RCTs. Of the crossover trials, 8 reported including a washout period ranging from 1 to 8 wk (29–36), whereas the remaining 6 studies did not report whether a washout period was included in the protocol (37–42). Although the GFR values after the dietary intervention were reported by all 28 studies, only 18 trials provided both pre/post change or post-only meta-analysis. This significant difference between low-protein and HP intakes was chosen, and thus the data from the usual diet was replaced with chicken (1.35 g/kg BW), and a low-protein diet (0.66 g/kg BW). In this situation, the greatest difference between low-protein and HP intakes was chosen, and thus the data from the usual diet and low-protein diet were compared. Furthermore, only data for subjects with normoalbuminuria were used in the analysis (31). Individual study characteristics and overall summary characteristics pertaining to participant sex, diabetic status, dietary characteristics, and GFR measurement type can be found in Tables 1 and 2.

**Diet protocol characteristics**

The dietary interventions ranged from 4 d to 104 wk. In 25 of the 28 trials participants underwent an HP or an NLP diet for the length of the intervention. In the remaining 3 crossover trials, participants underwent 3 different diet interventions as detailed above (31, 33, 39). Protein intakes in the NLP and HP groups differed substantially between trials at 1.81 ± 0.60 g · kg BW⁻¹ · d⁻¹ for the HP group and 0.93 ± 0.51 g · kg BW⁻¹ · d⁻¹ for the NLP group. Sixteen trials were designed for study participants to be in weight maintenance (29–42, 50, 55), 9 trials were designed to induce weight loss (43, 45, 46, 48, 49, 52–54, 56), and 3 trials involved both weight-loss and weight-maintenance phases (44, 47, 51). Of the studies involving both energy-restriction and energy-balance phases, 2 trials reported GFR data after both phases of the diet (44, 47). In this situation, the overall effect of HP compared with NLP intake across the full study was input into the main analysis and results from each phase of the trial (energy restriction or energy balance) were included in the subgroup analyses. The other trial that involved both energy restriction and balance only reported data at baseline and the end of the study (51), and thus was not included in subgroup analysis for energy intake. Data for dietary protein intake were provided in various formats, but all of the HP diets met the inclusion requirements for dietary intervention.

**Publication bias, heterogeneity, and risk of bias**

Funnel plots were visually inspected for publication bias. Little-to-moderate asymmetry was observed for the post-only, but not the pre/post, change; SMDs indicated the potential for publication bias. The chi-square test indicated significant heterogeneity for the pre/post change analysis (30.26; P = 0.02), but not the post-only analysis (15.8; P = 0.98). Furthermore, the I² test (pre/post change: I² = 44%, post-only: I² = 0%) indicated that there was moderate heterogeneity between trials included in the pre/post change analysis. This significant heterogeneity may have arisen because of substantial differences between trials pertaining to diet type (i.e., caloric restriction compared with energy balance), intervention length, mode of GFR measurement, and subject characteristics (BMI, age, pre-existing health conditions).

No trials were removed owing to risk of bias (Supplemental Table 1). Unclear risk domains predominated for random-sequence generation, allocation concealment, and selective reporting due to inadequate details provided in the methodologies of the trials. Two trials (34, 40) reported >3 unclear risk domains. Sensitivity analysis showed that removal of these trials from the analysis did not influence the overall result in either the pre/post change or post-only meta-analysis.
| Study (ref)     | Study design | Diet groups | Total, n | Women, % | n/Group | Diabetic (yes/no) | Mean age, y | Study duration, wk | Dietary protein sources | Daily protein intake | Diet type | GFR method | Pre (±) | Post (±) |
|----------------|--------------|-------------|----------|----------|---------|-------------------|-------------|-------------------|-----------------------|---------------------|-----------|------------|----------|----------|
| Antonio et al. (37) | X-over       | HP          | 12       | 0        | 12      | No                | 26          | 26.8              | 8                     | Usual dietary protein + whey protein | 3.3 g/kg | EB, ad libitum | eGFR (Eq not specified, mL · min⁻¹ · 1.73 m⁻²) | 96 ± 20  | 101 ± 18 |
| Antonio et al. (38) | X-over       | NLP         | 14       | 0        | 14      | No                | 26          | n.d.              | 24                    | Usual dietary protein + whey protein | 2.6 g/kg | EB, ad libitum | eGFR (Eq not specified, mL · min⁻¹ · 1.73 m⁻²) | 96 ± 20  | 102 ± 18 |
| Bergstrom et al. (29) | X-over      | HP          | 8        | 50       | 8       | No                | 26          | n.d.              | 1                     | Usual dietary protein               | 2.5 g/kg | EB, isocaloric | Inulin clearance (mL/min) | 95 ± 19  | 101 ± 17 |
| Brinkworth et al. (44) | PG          | HP          | 29       | 72       | 14      | No                | 52          | 34.0              | 6 wk: 12 wk ER; 56 wk EB | Dairy, meat, fish               | 0.3 g/kg | EAA tablets | Creatinine clearance (mL/min) | n.d.     | 100 ± 14 |
| Brinkworth et al. (43) | PG          | HP          | 68       | 63       | 33      | No                | 51          | 33.5              | 52                    | Dairy, poultry, meat, fish, nuts | 15%      | Meat, poultry | 100 ± 14  | 124 ± 40 |
| Chu et al. (39)     | X-over       | HR          | 6         | 0        | 6       | No                | 25          | 21.2              | 2                     | Meat, poultry               | 150 g    | EB, isocaloric | Creatinine clearance (mL/min) | n.d.     | 122 ± 15 |
| Frank et al. (30)   | X-over       | HP          | 24       | 0        | 24      | No                | 24          | 22.3              | 1                     | Plant and animal sources including dairy | 75 g     | Meat, poultry | Sinistrin clearance (mL/min) | n.d.     | 105 ± 14 |
| Friedman et al. (45) | PG          | HP          | 307      | 68       | 153     | No                | 46          | 36.1              | 104                   | Animal sources according to Dr. Atkins' New Diet Revolution Unlimited | ER, ad libitum | Creatinine clearance (mL/min) | 135 ± 35  | 139 ± 35 |
| Gross et al. (31)   | X-over       | NLP         | 15       | 27       | 15      | Yes               | 57          | 24.8              | 4                     | Usual diet except chicken replaces beef | 15%      | Beef, casein, egg white, wheat gluten | 123 g    | 133 ± 42  |
| Hegsted and Linkswiler (32) | X-over     | HP          | 6        | 100      | 6       | No                | 23–28       | 23                | 28                    | Beef, vegetable and milk protein only | 0.5–0.8 g/kg | EB, isocaloric | Creatinine clearance (mL/min) | n.d.     | 103 ± 5  |

(Continued)
| Study (ref)           | Study design | Diet groups | Total\(^2\) | Women, % | n/Group | Diabetic (yes/no) | Mean age, y | Mean BMI, kg/m\(^2\) | Study duration, wk | Dietary protein sources | Daily protein intake | Diet type | GFR method                  | Pre | Post   |
|----------------------|--------------|-------------|-------------|-----------|---------|------------------|-------------|---------------------|-------------------|-----------------------|----------------------|-----------|-----------------------------|-----|--------|
| Jenkinset al. (40)   | X-over       | HP          | 20          | 25        | 20      | No               | 56          | 26.0                | 4                 | Vegetable protein     | 27.4%                | EB, isocaloric  | Creatinine clearance (mL/min) | n.d. | 110 ± 31 |
| Johnston et al. (46) | PG           | HP          | 16          | 90        | 9       | No               | 19–54       | 28.9                | 6                 | Poultry, dairy, beans | 15.6%                | ER, isocaloric  | Creatinine clearance (mL · min\(^{-1}\) · m\(^{-2}\)) | 104 ± 25 | 85 ± 25 |
| Jurasczek et al. (33)| X-over       | HP          | 156         | 45        | 156     | No               | 54          | 30.2                | 6                 | Plant and animal protein | 25%                | EB, isocaloric  | eGFR (CKD epi, cystatin C, mL · min\(^{-1}\) · 1.73 m\(^{-2}\)) | 82 ± 17 | 85 ± 22 |
| Kerstetter et al. (34)| X-over     | HP          | 7           | 100       | 7       | No               | 26          | 23.0                | 1                 | Poultry, fish, meat, dairy | 2.1 g/kg            | EB, isocaloric  | eGFR (Eq not specified, mL/min) | 104 ± 13 | 116 ± 22 |
| Kim and Linkswiler (41)| X-over  | HP          | 6           | 0         | 6       | No               | 21–29       | n.d                 | 1.5               | Beef, casein, wheat gluten, vegetable sources | 0.7 g/kg            | EB, isocaloric  | Creatinine clearance (mL/min) | 98 ± 12 | 102 ± 10 |
| Larsen et al. (47)   | PG           | HP          | 99          | 52        | 53      | Yes              | 59          | 27–40               | 52 wk: 12 wk ER; 36 wk EB | Meat, dairy         | 47 g                  | EB, isocaloric  | eGFR (Eq not specified, mL · min\(^{-1}\) · 1.73 m\(^{-2}\)) | 70 ± 12 | 73 ± 18 |
| Leidy et al. (48)    | PG           | HP          | 46          | 100       | 21      | No               | 50          | 30.6                | 12                | Lean meat, chicken, fish | 15%                  | ER, isocaloric  | eGFR (MDRD, mL · min\(^{-1}\) · 1.73 m\(^{-2}\)) | 73 ± 15 | 76 ± 18 |
| Luscombe-Marsh et al. (51) | PG    | HP          | 57          | 56        | 27      | No               | 50          | 34.0                | 16-12 wk ER; 4 wk EB | Animal, dairy, whey | 2.4 g/kg             | ER, isocaloric  | eGFR (CKD epi, mL · min\(^{-1}\) · 1.73 m\(^{-2}\)) | 110 ± 9 | 114 ± 11 |
| Noakes et al. (52)   | PG           | HP          | 98          | 100       | 50      | No               | 49          | 32.0                | 12                | Lean meat, poultry, low-fat dairy | 1.2 g/kg            | EB, isocaloric  | eGFR (MDRD, mL · min\(^{-1}\) · 1.73 m\(^{-2}\)) | 66 ± 15 | 69 ± 19 |

(Continued)
| Study (ref) | Study design | Diet groups | Total | Women, % | n/Group | Diabetic (yes/no) | Mean age, y | Mean BMI, kg/m² | Study duration, wk | Dietary protein sources | Daily protein intake | Diet type | GFR method | Pre | Post |
|------------|--------------|-------------|-------|----------|---------|------------------|-------------|-----------------|------------------|-----------------------|---------------------|-----------|------------|------|------|
| Roughead et al. (42) | X-over | HP | 15 | 100 | 15 | No | 60 | 26.5 | 8 | Meat, poultry | 20% | EB, isocaloric | Creatinine clearance (mL/min) | n.d. | 83 ± 11 |
| Skov et al. (53) | PG | NLP | 50 | 76 | 25 | No | 40 | 30.4 | 24 | Vegetable | 12% | Diabetic, meat, poultry, fish, offal | 25% | ER, ad libitum | 51 Cr-EDTA clearance (mL/min) | 106 ± 15 | 111 ± 18 |
| Tay et al. (54) | PG | NLP | 115 | 43 | 58 | Yes | 58 | 34.6 | 52 | Poultry, meat, fish, dairy | 28% | ER, isocaloric | eGFR (CKD epi, mL·min⁻¹·1.73 m⁻²) | 114 ± 19 | 105 ± 16 |
| Teunissen-Beerlman et al. (55) | PG | HP | 48 | 30 | 24 | No | 55 | 29.0 | 4 | Protein isolate supplement (pea, soy, egg white, milk) | 17% | EB, ad libitum | Insulin clearance (mL/min) | 137 ± 26 | 134 ± 26 |
| Wagner et al. (35): young | X-over | NLP | 12 | 67 | 12 | No | 31 | 25.1 | 1 | Meat, dairy, egg white | 2 g/kg | EB, isocaloric | eGFR (MDRD, mL·min⁻¹·1.73 m⁻²) | n.d. | 95 ± 11 |
| Wagner et al. (35): old | X-over | NLP | 10 | 70 | 10 | No | 60 | 25.8 | 1 | Meat, dairy, egg white | 0.5 g/kg | EB, isocaloric | eGFR (MDRD, mL·min⁻¹·1.73 m⁻²) | n.d. | 92 ± 10 |
| Walland et al. (36): young | X-over | HP | 10 | 50 | 10 | No | 24 | 23.3 | 1.5 | Meat, dairy, egg white | 0.5 g/kg | EB, isocaloric | lothalamate clearance (mL·min⁻¹·SA⁻¹) | n.d. | 69 ± 10 |
| Walland et al. (36): old | X-over | NLP | 9 | 44 | 9 | No | 70 | 27.2 | 1.5 | Meat, dairy, egg white | 2.1 g/kg | EB, isocaloric | lothalamate clearance (mL·min⁻¹·SA⁻¹) | n.d. | 128 ± 6 |
| Wycherly et al. (56) | PG | NLP | 64 | 0 | 32 | No | 51 | 33.0 | 52 | Low-fat dairy, meat, fish | 35% | ER, isocaloric | Creatinine clearance (mL·min⁻¹·1.73 m⁻²) | 106 ± 25 | 110 ± 40 |

1 CKD epi, Chronic Kidney Disease Epidemiology Collaboration equation; EAA, essential amino acid; EB, energy balance; eGFR, estimated glomerular filtration rate; Eq, equation; ER, energy restriction; GFR, glomerular filtration rate; HP, high-protein; MDRD, Modification of Diet in Renal Disease equation; n.d., not described/determined; NLP, normal- or low-protein; PG, parallel-group study design; Post, post-intervention; Pre, pre-intervention; ref, reference; SA, surface area; X-over, crossover study design.

2 Subject numbers are reported for the number of subjects included in the renal function assessment within each study and may be less than the total subject number for the study.

3 Values are means ± SDs.
TABLE 2  Summary of study characteristics of studies included in the meta-analysis of whether higher-protein intakes affect kidney function in healthy people

| Study characteristic                  | Study references | Notes |
|---------------------------------------|------------------|-------|
| Study design                          |                  |       |
| Parallel group                        | (43–56)          |       |
| Crossover                             | (29–42)          |       |
| Includes washout                      | (29–36)          |       |
| No washout                            | (37–42)          |       |
| Type 2 diabetes                       | (31, 47, 50, 54) |       |
| Sex                                   |                  |       |
| Men                                   | (30, 37, 39, 41, 49, 56) |       |
| Women                                 | (32, 34, 42, 48, 52) |       |
| Both                                  | (29, 31, 33, 35, 36, 40, 43–47, 50, 51, 53–55) |       |
| Diet                                  |                  |       |
| Isocaloric                            |                  |       |
| Modified CHO                          | (33–35, 40, 42, 44, 47, 48, 50, 52, 56) |       |
| Modified fat                          | (36, 49, 51)     |       |
| Modified both                         | (29, 30, 32, 41, 43, 45, 46, 54) |       |
| Ad libitum                            |                  |       |
| Modified CHO                          | (31, 53, 55)     |       |
| Food provided                         |                  |       |
| All                                   | (29, 32–36, 39–42, 46, 49) | Protein powder provided to HP group |
| Some                                  | (37, 38)         | 30–60% of total energy provided |
|                                       | (48, 51, 52, 54) | 60% provided during weeks 1–12 |
|                                       | (56)             |       |
| Dietary advice only                   | (30, 31, 43–45, 47, 50, 55) | Includes counselling, detailed menus, diet tools (i.e., food scales) |
| Major sources of protein provided    |                  |       |
| Yes                                   | (29–35, 37–44, 46–49, 51–56) | For HP only |
|                                       | (45, 50)         |       |
| No                                    | (36)             |       |
| Type of protein                       |                  |       |
| Animal + vegetable                    | (29–39, 41–56)   |       |
| Non-animal                            | (40)             |       |
| Energy status                         |                  |       |
| Energy balance                        | (29–42, 50, 55)  |       |
| Energy restriction                    | (43, 45, 46, 48, 49, 52–54, 56) |       |
| Both                                  | (44, 47, 51)     |       |
| Diet adherence measured               |                  |       |
| Yes                                   | (30–40, 43, 44, 46–53, 55, 56) | Includes participant diet logs and urinary output measures |
| No                                    | (29, 32, 41, 42, 45) |       |
| Study completion rates                |                  |       |
| All completed                         | (29, 32, 37, 39, 41, 49, 53, 54) |       |
| Dropouts reported                     | (30, 31, 33, 35, 36, 38, 42–48, 50–52, 55, 56) | Drop-out rates similar between groups |
| Text implies all completed            | (34, 40)         |       |
| GFR measurement type                  |                  |       |
| Isotope clearance                     | (31, 36, 53)     |       |
| Creatinine clearance                  | (32, 39–42, 44–46, 51, 52, 56) | $^{125}$I-iotalamate, $^{99m}$technetium-DTPA, $^{51}$chromium-EDTA |
| Inulin/sinistrin clearance            | (29, 30, 55)     |       |
| eGFR                                  | (33–35, 37, 38, 43, 47–50, 54) |       |

1 CHO, carbohydrate; DTPA, diethylenetriaminepentacetate; eGFR, estimated glomerular filtration rate; GFR, glomerular filtration rate; HP, high-protein.

**Certainty in the evidence**

The summary of findings from the GRADE assessment is shown in Table 3. When applying the GRADE approach, we identified serious issues of risk of bias or limitations in study design, specifically related to poor reporting in the domains of random-sequence generation and allocation concealment. In addition, we also identified serious issues of inconsistency given the unexplained heterogeneity and serious issues of imprecision. The quality of the evidence across outcomes was low to very low.

**Meta-analysis**

**Overall effect of HP compared with NLP diets on GFR.**

The pooled estimates of effect size (95% CIs) for the post-only and pre/post change analyses are shown in Figures 2 and 3. Overall, there was a trivial effect of consuming an HP diet compared with an NLP diet on GFR in the combined post-only analysis using the generic inverse-variance method ($P = 0.002$), whereas there was no effect in the pre/post change analysis using continuous data and the inverse-variance method ($P = 0.16$).
Effect of trial type on the effect of HP compared with NLP diets on GFR. Given the potential confounding influence of the previous intervention influencing the secondary intervention with crossover trials, we conducted a subgroup analysis on the basis of intervention type. In the post-only comparison, there was a trivial effect for HP intake to result in a higher GFR than NLP intake for parallel-group trials when analyzed using either continuous data and the inverse-variance method or generic inverse-variance methods (P = 0.004; Figure 2). There was no effect of HP consumption on post GFR in the crossover trials (P = 0.29) and no differences between subgroups (P = 0.88; Figure 2). When only parallel-group trials were included in the pre/post change analysis, the results of the full analysis were maintained (P = 0.34; Figure 3). Sensitivity analysis showed that removing the crossover studies that did not include a washout period did not influence the overall result in either the post-only or pre/post change analyses.

Effect of post-only compared with pre/post change on GFR. There was a small, but significant effect of HP consumption on GFR when post-only values from studies that reported GFR before and after the intervention were analyzed (SMD: 0.20; 96% CI: 0.07, 0.33; P = 0.003); however, when the change induced by the dietary intervention in these same studies was analyzed, the effect size was not significant (SMD: 0.10; 95% CI: −0.09, 0.30; P = 0.3), with no difference between the subgroups (P = 0.44). This analysis included crossover trials; however, the results were not affected when the analysis was conducted without the crossover trials.

Effect of GFR measurement type on the overall effect of HP compared with NLP diets on GFR. There was no difference in the effect size of HP compared with NLP diets on GFR dependent on whether a study determined kidney function using measurements of solute clearance or estimated GFR (eGFR) from serum creatinine concentrations for pre/post change (clearance measures—SMD: 0.17; 95% CI: −0.02, 0.35; P = 0.07; eGFR—SMD: 0.09; 95% CI: −0.15, 0.34; P = 0.45; between-subgroup comparison, P = 0.63). In the post-only analysis, although there were no differences between subgroups (P = 0.58); however, there was a small but statistically significant effect of HP intake when studies used clearance methods (SMD: 0.22; 95% CI: 0.06, 0.39; P = 0.008), but not eGFR (SMD: 0.16; 95% CI: 0.03, 0.34; P = 0.09).

Effects of energy intake during HP compared with NLP diets on GFR. Different results were found when a subanalysis was performed on studies that involved energy restriction compared with those that involved energy balance. For this comparison, the study by Luscombe-Marsh et al. (51) was excluded as detailed above and the specific results pertaining to the energy-restriction and energy-balance portions of Larsen et al. (47) and Brinkworth et al. (44) were used. For the post-only analysis there was no difference between HP and NLP consumption on GFR when studies were conducted in energy balance (SMD: 0.06; 95% CI: −0.2, 0.33; P = 0.64); however, there was a small effect for post HP to be higher after HP intake when the study was conducted in energy deficit (SMD: 0.20; 95% CI: 0.04, 0.35; P = 0.1). For the pre/post change analysis, there was a trivial effect for the change induced by HP intakes to be greater when the study was conducted in energy balance (SMD: 0.18; 95% CI: 0.02, 0.34; P = 0.03). The effect of HP intakes on the change in GFR during energy balance was mainly due to the effects seen in the first 8 wk of consuming an HP diet (SMD: 0.30; 95% CI: 0.10, 0.51; P = 0.004), with longer-term HP consumption not influencing GFR any differently than NLP consumption (intervention length of 8–24 wk—SMD: −0.07; 95% CI: −0.48, 0.33; P = 0.73; intervention length >24 wk—SMD: 0.00; 95% CI: −0.35, 0.34; P = 0.99). When the studies were conducted during energy restriction, the change induced by HP intakes was not different from that with NLP intakes (SMD: 0.09; 95% CI: −0.15, 0.34; P = 0.46).

Effects of health status on GFR during HP and NLP diets. A subanalysis was conducted in participants with type 2 diabetes, given their elevated risk for kidney disease (57). In both the pre/post change and post-only analysis there was no difference in GFR between conditions of an HP- and NLP-containing diet (pre/post change—SMD: −0.11; 95% CI: −0.35, 0.14; P = 0.40; post-only—SMD: 0.11; 95% CI: −0.13, 0.34; P = 0.37).

---

### TABLE 3 Summary of findings from the GRADE assessment of studies included in the meta-analysis of whether higher-protein intakes affect kidney function in healthy people

| Outcomes       | Risk with low protein (95% CI) | Risk with high protein (95% CI) | Participants, n (studies, n) | Quality of the evidence (GRADE) |
|----------------|--------------------------------|--------------------------------|-----------------------------|---------------------------------|
| Pre/post change| —                              | 0.11 higher (−0.05 to 0.27)     | 1547 (19 RCTs)              | Very low1,5                      |
| Post-GFR       | —                              | 0.19 higher (0.07 to 0.32)      | 1688 (31 RCTs)              | Low6                           |

1GFR, glomerular filtration rate; GRADE, Grades of Recommendation, Assessment, Development, and Evaluation; RCT, randomized controlled trial; SMD, standardized mean difference.
2The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
3GRADE Working Group grades of evidence are as follows—high quality: we are very confident that the true effect lies close to that of the estimate of the effect; moderate quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; low quality: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect; very low quality: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
4Most studies had serious issues of reporting and were classified as unclear for the domains of random-sequence generation and allocation concealment.
5Unexplained heterogeneity (P = 0.02, I² = 44%). The 95% CI includes a negligible reduction, no difference, and a moderate increase in GFR (−0.05 to 0.27).
**Effects of intervention length on GFR during HP and NLP diets.** A subgroup analysis was conducted on trials with durations of <8 wk, 8–24 wk, and >24 wk. The post-only analysis showed that HP intakes influenced post GFR to a greater extent after longer duration interventions (intervention length of 8–24 wk—SMD: 0.27; 95% CI: 0.06, 0.48; P = 0.01; >24 wk—SMD: 0.20; 95% CI: 0.03, 0.37; P = 0.02), with no differences in the effect of diet on GFR between HP and NLP intakes with interventions of <8 wk (SMD: −0.06; 95% CI: −0.39, 0.27; P = 0.72) and no differences between subgroups (P = 0.78). When weight-loss studies were removed from this analysis there was no influence of intervention length on post GFR between HP and NLP groups (<8 wk—SMD: 0.02; 95% CI: −0.39, 0.43; P = 0.93; 8–24 wk—SMD: 0.10; 95% CI: −0.31, 0.51; P = 0.62). In the pre/post change comparison, there was no influence of intervention length on the change in GFR between HP and NLP groups (intervention length of <8 wk—SMD: 0.14; 95% CI: −0.22, 0.5; P = 0.45; 8–24 wk—SMD: 0.11; 95% CI: −0.26, 0.48; P = 0.55; >24 wk—SMD: 0.07; 95% CI: −0.10, 0.24; P = 0.43). Removal of the crossover trials from the pre/post change analysis did not influence the results.

**Effect of varying fat or carbohydrate intake during HP diets on GFR.** To increase the proportion of energy intake from protein there needs to be a reduction in either carbohydrate or fat intake if diets are to remain isocaloric. Whether a study chose to modify carbohydrate or fat intake did not influence the results (fat—post-only SMD: 0.19; 95% CI: −0.39, 0.77; P = 0.52; pre/post change SMD: 0.27; 95% CI: −0.13, 0.67; P = 0.18; carbohydrate—post-only SMD: 0.18; 95% CI: 0.01, 0.35; P = 0.06; pre/post change SMD: 0.13; 95% CI: −0.08, 0.34; P = 0.22; both—post-only SMD: 0.24; 95% CI: 0.02, 0.41; P = 0.02; pre/post change SMD: 0.06; 95% CI: −0.26, 0.37; P = 0.72).

**Meta-regression**

The results from the full-model meta-regressions are presented in Table 4. In the pre/post change meta-regression, when all covariates were combined, differences in protein intake, trial
length, age, diabetic status, and energy intake status did not explain any of the variance ($\tau^2 = 0.12$) in the changes in GFR ($P = 0.93$). Univariate meta-regressions on changes in GFR in the pre/post change analysis are also presented in Table 4. Differences in protein intake ($P = 0.42$), trial length ($P = 0.84$), age ($P = 0.59$), diabetic status ($P = 0.13$), and whether the study was conducted in energy restriction or energy balance ($P = 0.71$) did not explain any of the heterogeneity of the effect of protein intake on GFR. None of the additional covariates examined [weight ($P = 0.44$), energy intake ($P = 0.54$), difference in protein intake as a percentage of total energy intake ($P = 0.89$), absolute difference in protein intake ($P = 0.49$), or study design (parallel-group compared with crossover RCT, $P = 0.61$)] explained any of the variance in the change in GFR (data not shown). Removal of the crossover trials from the meta-regression did not influence the results.

In the post-only meta-regression there was no unexplained variance ($\tau^2$); and thus, unsurprisingly, when all covariates were combined, differences in protein intake, trial length, age, diabetic status, and energy intake status did not explain any of the variance in the change in GFR ($P = 0.46$; Table 4). Univariate meta-regressions on post GFR also found that none of the covariates explained any of the variability in GFR (Table 4). Furthermore, none of the additional covariates examined [body weight ($P = 0.93$), study design ($P = 0.74$), energy intake ($P = 0.40$), difference in protein intake to percentage of total energy intake ($P = 0.16$), or absolute difference in protein intake ($P = 0.42$)] explained any of the variability in GFR.

Dose-response analysis

Given the large variability in the protein doses used within each study, we examined whether there was a dose-response effect of protein on GFR after the intervention or whether the change in GFR in response to the intervention was influenced by protein dose. Linear regression analysis indicated that there was a dose-response effect of protein dose on GFR after the intervention (Figure 4A); however, protein dose did not explain the change in GFR in response to the intervention (Figure 4B). Biphasic regression analysis was not significant ($P = 0.38$), indicating that the linear model best fit the data.

**Discussion**

We conducted a systematic review and meta-analysis to determine the effects of consuming an HP ($1.81 \pm 0.60$ g · kg BW$^{-1}$ · d$^{-1}$) compared with an NLP ($0.93 \pm 0.51$ g · kg BW$^{-1}$ · d$^{-1}$) diet on kidney function in individuals without CKD. Similar to the results of a previous meta-analysis (14), we report that there was a trivial effect for GFR to be greater in the HP group compared with the NLP group when GFR was examined using only post data. However, and in contrast to the post-only analysis, the novel finding of this meta-analysis is that when the change in GFR from baseline was compared, there was no difference between the HP and NLP groups. Furthermore, when we directly compared the effect sizes of post-only with pre/post change data in the 18 studies that included these data, the effect size was significant when the post-only values were compared, but not when the pre/post change values were compared. These discordant findings highlight the need to include pre/post change analyses as well as post-only analyses when examining the effect of a nutritional intervention on a health outcome. Our subgroup analyses further confirmed this need because different results were found depending on whether post-only or pre/post change data were analyzed. The post-only comparison found a small effect of consuming an HP diet when studies were
TABLE 4  Meta-regression analyses of studies included in the meta-analysis of whether higher-protein intakes affect kidney function (GFR) in healthy people

| Model                        | n²   | Coefficient (95% CI) | τ² | Adjusted R², % | I², % | P     |
|------------------------------|------|----------------------|----|----------------|-------|-------|
| **Pre/post change analysis** |      |                      |    |                |       |       |
| No covariates                | 18   | 0.11 (−0.05, 0.27)   | 0.05 | 44             | 0.16  |
| Univariate                   |      |                      |    |                |       |       |
| Difference in protein intake, g · kg⁻¹ · d⁻¹ | 16   | 0.32 (−0.51, 1.16)   | 0.06 | 5              | 44    | 0.42  |
| Trial length, wk             | 18   | 0.00 (−0.01, 0.01)   | 0.06 | −27            | 49    | 0.84  |
| Age, y                       | 18   | −0.01 (−0.02, 0.01)  | 0.05 | −4             | 48    | 0.59  |
| Diabetic, yes/no             | 18   | −0.31 (−0.73, 0.11)  | 0.02 | 57             | 37    | 0.13  |
| Energy restriction, yes/no   | 18   | 0.06 (−0.37, 0.26)   | 0.07 | −10            | 51    | 0.71  |
| All covariates               | 16   | 0.12                 |     | −67            | 56    | 0.93  |
| Difference in protein intake, g · kg⁻¹ · d⁻¹ | 16   | 0.15 (−1.63, 1.92)   |     | 1.00           |       |       |
| Trial length, wk             | 16   | 0.00 (−0.02, 0.02)   |     | 1.00           |       |       |
| Age, y                       | 16   | −0.00 (−0.04, 0.04)  |     | −27            | 49    | 0.84  |
| Diabetic, yes/no             | 16   | −0.30 (−1.11, 0.51)  |     | 84             |       |       |
| Energy restriction, yes/no   | 16   | 0.04 (−0.42, 0.50)   |     | 1.00           |       |       |
| Post-only analysis           |      |                      |    |                |       |       |
| No covariates                | 30   | 0.19 (0.07, 0.32)    | 0.00 | 0              | 0.002 |
| Univariate                   |      |                      |    |                |       |       |
| Difference in protein intake, g · kg⁻¹ · d⁻¹ | 28   | −0.13 (−0.71, 0.45)  | 0.00 | 0              | 0.66  |
| Trial length, wk             | 30   | −0.00 (−0.00, 0.01)  | 0.00 | 0              | 0.55  |
| Age, y                       | 30   | 0.00 (−0.01, 0.02)   | 0.00 | 0              | 0.57  |
| Diabetic, yes/no             | 30   | −0.10 (−0.39, 0.19)  | 0.00 | 0              | 0.48  |
| Energy restriction, yes/no   | 30   | −0.04 (−0.26, 0.19)  | 0.00 | 0              | 0.75  |
| All covariates               | 28   | 0.00                 |     | 100            | 0     | 0.46  |
| Difference in protein intake, g · kg⁻¹ · d⁻¹ | 28   | 0.00 (−0.87, 0.87)   |     | 1.00           |       |       |
| Trial length, wk             | 28   | 0.01 (−0.00, 0.01)   |     | 0.73           |       |       |
| Age, y                       | 28   | 0.01 (−0.01, 0.03)   |     | 0.88           |       |       |
| Diabetic, yes/no             | 28   | −0.31 (−0.71, 0.08)  |     | 0.38           |       |       |
| Energy restriction, yes/no   | 28   | −0.06 (−0.29, 0.18)  |     | 0.99           |       |       |

1GFR, glomerular filtration rate.
2Number of studies in the analysis.
3Pre- to post-change analysis is reported for studies that provided GFR values both pre- and post, allowing for determination of the effect of the nutritional intervention on the change in GFR.
4Post-only analysis is reported for all included trials and is determined on the basis of the post-intervention GFR only.

Conducted in energy restriction but not in energy balance. On the other hand, the pre/post change analysis found a trivial effect of consuming an HP diet when studies were conducted in energy balance but not in energy restriction. Furthermore, although the post-only analysis found that intervention length and method of GFR measurement influenced whether GFR was higher after the intervention with HP intakes, the pre/post change analysis did not. Similarly, we found a dose-response effect for protein intake on the post GFR; however, protein dose was not related to the change in GFR in response to the intervention.

One of the main reasons for conducting this meta-analysis was to examine whether the results obtained from comparing post GFRs were similar to those obtained when the change in GFR induced by the intervention were compared. Convention

FIGURE 4  Linear regression analysis showing the dose-response effect between increasing protein intake and post eGFR ($r = 0.332, P = 0.03$) (A) and the change in GFR in response to the intervention ($r = 0.184, P = 0.33$) (B) in healthy people. GFR and ΔGFR were reported as mL/min or as mL · (min · 1.73 m²)⁻¹ depending on whether studies used clearance or eGFR measurements. BW, body weight; eGFR, estimated glomerular filtration rate; GFR, glomerular filtration rate.
stipulates that it is appropriate to conduct meta-analysis on post-only values from, for example, pharmaceutical trials in which participants enter the trial with no exposure to the drug before the intervention. However, participants entering a nutritional intervention will have had varying exposures to different macronutrients (i.e., protein), which may influence the baseline GFR as well as the direction of change in the GFR response upon commencement of the intervention. Proper the baseline GFR as well as the direction of change in the different macronutrients (i.e., protein), which may influence a nutritional intervention will have had varying exposures to drug before the intervention. However, participants entering which participants enter the trial with no exposure to the post-only values from, for example, pharmaceutical trials in stipulates that it is appropriate to conduct meta-analysis on were included. Given the interindividual variability in GFR when only studies involving individuals with type 2 diabetes HP diet on GFR. Similarly, differing results were found for post GFR, whereas the pre/post change analysis was not significant (SMD: 0.24 compared with 0.12). These findings suggest that the post-only analysis exaggerated an effect of an HP diet on GFR. Similarly, differing results were found for post-only compared with pre/post change when studies were conducted in energy balance and energy deficit. Furthermore, although neither were significantly different, the direction of effect differed between post-only and pre/post change analyses when only studies involving individuals with type 2 diabetes were included. Given the interindividual variability in GFR within a healthy population (58, 59), simply comparing the GFR between HP and NLP groups after the intervention and inferring that the differences are the result of the intervention may lead to inaccurate interpretations. Although it is unclear which method is the best to use when conducting a meta-analysis, these findings do bring into question whether we can rely exclusively on the results from post-only analyses because the current analysis showed differences in the magnitude and direction of results depending on whether post-only or pre/post change values were analyzed. Future nutrition studies should include measurements of GFR (or any outcome of interest) both before and after the intervention to allow for determination of both post-only and pre/post change effects.

HP or protein-supplemented diets are known to induce greater muscle hypertrophy during resistance training (1) and to preserve muscle mass (2, 3) and promote fat loss (2) during energy restriction. Despite these well-known benefits there may be reluctance to recommend HP intakes due to an ensuing increase in GFR, which some have argued leads to glomerular damage and eventual kidney failure (9). The link between glomerular hyperfiltration and kidney dysfunction was originally proposed by Brenner et al. (9), who suggested that the increase in GFR was compensatory in response to nephron loss. Indeed, in response to kidney injury resulting in nephron loss, glomerular hypertension has been shown to precede progressive kidney damage in animal models (60, 61). However, in these situations, the increase in GFR occurred at the single-nephron level, whereas in humans in response to protein-feeding or other stimuli, such as pregnancy or nephrectomy, glomerular hyperfiltration occurs at the whole-kidney level as a result of increased kidney blood flow (62, 63). In fact, the capacity to increase GFR in response to protein feeding, known as kidney functional reserve, is a normal adaptive function of the kidney to increase solute clearance in response to an increase in solute load (i.e., nitrogen load). Importantly, this adaptive response does not represent a risk factor for the development of CKD (62, 64). Indeed, GFR increases by ~65% during pregnancy (65) but does not increase the risk of kidney disease (66). Furthermore, despite significant hypertrophy and hyperfiltration in the remaining kidney after nephrectomy, kidney function remains normal over a prolonged period (>20 y) (67, 68). A recent trial found that after kidney transplant there was a negative correlation between protein intake and mortality and graft failure in normal-weight individuals with an eGFR >45 mL · min⁻¹ · 1.73 m⁻² (69), suggesting a protective effect of protein intake on kidney health. Moreover, despite numerous studies that found that an HP diet increases GFR (30, 33, 49, 53, 70, 71), to date there is no evidence linking HP intake to kidney disease in healthy individuals or those at risk of kidney disease due to pre-existing conditions such as obesity, hypertension, or dyslipidemia (62). Furthermore, animal studies have shown that markers of renal damage do not differ in obese rats fed a high-mixed-protein diet for 12 wk as compared with those fed a lower-protein diet, despite an increase in kidney size (72). In addition, monocyte chemoattractant protein 1 (MCP-1) concentration, a known mediator of kidney disease susceptibility (73), was lower in the high-mixed-protein group (72). These animal data again highlight that increased kidney size and GFR are not linked to kidney damage and disease. Together, our meta-analysis and other lines of evidence provide no evidence that the increase in GFR in response to an increase in blood solute load increases the risk of CKD.

Previous trials have found that HP intake increases GFR (30, 33, 49, 53, 70, 71). A critical consideration, however, is what this finding implies because it alone is not evidence that the risk of CKD is modified. With increasing age there is a progressive decline in GFR, ranging from 4 to 8 mL/min per decade (74), and therefore what is considered to be a normal GFR changes over the life span. Of the studies included in this meta-analysis, only 2 studies (45, 51) reported mean GFR values above what would be considered to be within the normal range for the age of the subjects tested (74).

This systematic review and meta-analysis included trials examining the effect of an HP compared with an NLP diet on GFR. Although not the main focus of the systematic search, thus not included in the meta-analysis, several trials reported on the effect of the dietary interventions on albumin excretion rate. Albumin excretion rate is used as a marker of kidney damage and can be used to detect and stage kidney disease (75), and thus if HP consumption was inducing damage to the kidney you would expect to see an increase in albumin excretion. Of the 8 trials (30, 31, 43, 45, 47, 50, 53, 54) that reported on the effects of an HP compared with an NLP diet on albumin excretion, only 1 trial found that an HP diet increased the albumin excretion rate (30). The other trials found no difference in the change in albumin excretion between HP and NLP diets. These findings once again suggest that consuming an HP diet does not negatively affect kidney function in healthy individuals.

Given the various study populations and study interventions included in this meta-analysis we conducted subgroup analyses to determine whether the overall results of the analysis were upheld in different situations. Of particular interest was the finding in individuals with type 2 diabetes, in whom there was no difference in kidney function with the consumption of an HP diet. This finding was true whether examining post-only or pre/post change in studies ranging in duration from 3 to 52 wk. These findings are in line with a recent meta-analysis that found no benefit to consuming a lower-protein diet in individuals.
with type 2 diabetes (76) and provide further support that HP diets do not cause a decline in kidney function even in those individuals at higher risk of kidney damage. We acknowledge, however, the small number of studies included in this and the other subgroup analyses, so our findings need to be interpreted with caution.

The current analysis found a dose-dependent effect of increasing protein intake on post GFR. Average protein doses in the included trials were 0.93 ± 0.51 and 1.81 ± 0.60 g · kg BW−1 · d−1 in the NLP and HP groups, respectively. Interestingly, although the dose-response effect of protein on post GFR was significant, there was no relation between protein dose and the change in GFR after the intervention. Although our dose-response relation does not appropriately weight each study on the basis of their sample and effect size as with a meta-regression (see Table 4), we present Figure 4 as a simplified representation that highlights the difficulty in interpreting data from post values because they show that an increasing protein dose does not induce a greater increase in GFR. Furthermore, meta-regression analysis did not find that the difference in protein dose explained any of the unexplained variance in the pre/post change analysis. These findings indicate that the magnitude of the change in GFR in response to differing protein intakes is not related to the magnitude of the difference in protein intakes between the HP and NLP groups. Taken together, the results of the dose-response and meta-regression analyses again bring in question the validity of determining the effect of an intervention on GFR by only comparing the post values.

As with any meta-analysis there are some inherent limitations. A concern when including crossover trials in a meta-analysis is the risk of carryover between arms of the trial (77). Although the potential for carryover with crossover trials exists, including a washout period between arms of the trial mitigates an impact of carryover from occurring (78). In the current analysis, 8 (29–36) of the 14 crossover trials indicated that they included a washout period in their study design. The removal of the 6 crossover trials that did not include a washout period between arms did not influence the overall results of the meta-analysis in either the pre/post change or post-only analyses. The effect size for crossover studies in the post-only analysis was slightly larger than that of the parallel-group trials (SMD: 0.22 compared with 0.19); however, the effect size was not significant for crossover studies, although it was for parallel-group trials, indicating a greater degree of variability in the crossover trials. Because of the risk of carryover in crossover trials, the use of post values, not change from baseline, is preferred when including crossover trials in a meta-analysis (79). The majority of trials that included pre- and post values were parallel-group trials (14 of 18 studies). To ensure that the inclusion of crossover trials in the pre/post change analysis did not influence the overall result, we conducted a subgroup analysis. The removal of the crossover trials in the pre/post change analysis resulted in a slight decrease in effect size (SMD: 0.11 compared with 0.09); however, neither of these analyses were significant. Overall, across all of the analyses included in this meta-analysis, the inclusion of crossover trials did not affect any of the results.

Another limitation of the current analysis was the overall unclear risk of bias of the included trials. Only 4 of the included trials reported the method they used to randomly assign participants into groups (47, 49, 54, 56). Furthermore, only 2 trials (47, 54) provided adequate information to ascertain that group allocation sequence was concealed. These selection bias issues are less of a concern for the crossover trials because all participants completed both arms of the trial; however, crossover trials have their own inherent limitations (i.e., potential for carryover; see discussion above). The overall risk of the unclear risk of selection bias on the results of the analysis is unknown. The results of this analysis highlight that future RCTs investigating the impact of protein intake on kidney function should use strategies to maximize validity and minimize bias using good study design.

In summary, the results of the current meta-analysis suggest a nonexistence or trivial effect of HP consumption on GFR in individuals with normal kidney function. These findings are in line with statements from the WHO (80) and Institute of Medicine (81) on protein intake and kidney function (82). Furthermore, there is no evidential link that shows that HP intake somehow leads to declines in renal function in otherwise healthy persons and, as our analysis indicates, even in populations with greater risk for declines in renal function such as those with type 2 diabetes. Given the proposed advantages of consuming HP diets to promote muscle hypertrophy during resistance training, high-quality weight loss during energy restriction, and maintenance of muscle mass with aging, the finding that an HP diet does not negatively affect kidney function is of relevance.

Acknowledgments
We thank Alonso Carrasco-Labra from the Department of Health Research Methods, Evidence, and Impact for conducting the GRADE assessment and R Bryan Rumble, Guideline Specialist at the American Society of Clinical Oncology, for providing advice and expertise in study design. The authors’ responsibilities were as follows—SMP, MCD, KSB, and LB: conceived and designed the study. MCD and AS: carried out the data extraction; MCD, AS, and RWM: carried out the data analysis; MCD, RWM, and SMP: drafted the manuscript; MCD, AS, KSB, LB, RWM, and SMP: contributed to editing and agreed on the final contents of the manuscript; and all authors: read and approved the final manuscript.

References
1. Cermak N, Res P, de Groot L, Saris H, van Loon L. Protein supplementation augments the adaptive response of skeletal muscle to resistance-type exercise training: a meta-analysis. Am J Clin Nutr 2012;96:1454–64.
2. Wycherley T, Moran L, Clifton P, Noakes M, Brinkworth G. Effects of energy-restricted high-protein, low-fat compared with standard-protein, low fat diets: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2012;96(6):1281–98.
3. Josse A, Atkinson S, Tarnopolsky M, Phillips S. Increased consumption of dairy foods and protein during diet- and exercise-induced weight loss promotes fat mass loss and lean mass gain in overweight and obese premenopausal women. J Nutr 2011;141(9):1626–34.
4. Bauer J, Biolo G, Cederholm T, Cesari M, Cruz-Jentoft A, Morley J, Phillips S, Sieber C, Stehle P, Teta D, et al. Evidence-based recommendation for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. J Am Med Dir Assoc 2013;14(8):542–59.
5. Deutz N, Bauer J, Barazzoni R, Biolo G, Boirie Y, Bosy-Westphal A, Cederholm T, Cruz-Jentoft A, Krzmaric Z, Nair K, et al. Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN Expert Group. Clin Nutr 2014;33(6):929–36.
6. Hartman J, Tang J, Wilkinson S, Tarnopolsky M, Lawrence R, Fullerton A, Phillips S. Consumption of fat-free fluid milk after resistance exercise promotes greater lean mass accretion than does consumption of soy or carbohydrate in young, novice, male weightlifters. Am J Clin Nutr 2007;86(2):373–81.
65. Calderone J, Zadshir A, Norris K. A survey of kidney disease and risk-factor information on the World Wide Web. Med Gen Med 2004;6(4):3.

66. Higashihara E, Horie S, Takeuchi T, Natahara K, Aso Y. Long-term consequence of nephrectomy. J Urol 1990;143(2):239–43.

67. Regazzoni B, Genton N, Pelet J, Drukker A, Guignard J. Long-term follow up of renal functional reserve capacity after unilateral nephrectomy in childhood. J Urol 1998;160(3 Part I):844–8.

68. Deetman PE, Said MY, Kromhout D, Dullaart RPF, Kootstra-Ros JE, Sanders JFF, Seelen MA, Robs ROB, Navis G, Joosten MM, et al. Urinary urea excretion and long-term outcome after renal transplantation. Transplantation 2015;99(5):1009–15.

69. Chan A, Cheng M, Keil L, Myers B. Functional response of healthy and diseased glomeruli to a large, protein-rich meal. J Clin Invest 1988;81:245–54.

70. Simon A, Lima P, Almerinda M, Alves V, Bottini P, de Faria J. Renal haemodynamic responses to a chicken or beef meal in normal individuals. Nephrol Dial Transplant 1998;13:2261–4.

71. Devassy J, Wociak J, Ibrahim N, Zahradkova P, Taylor C, Aukema H. Mixed compared with single-source proteins in high-protein diets affect kidney structure and function differently in obese half Zucker rats. Appl Physiol Nutr Metab 2017;42(2):131–41.

72. Murea M, Register T, Divers J, Bowden D, Carr J, Hightower C, Xu J, Smith S, Hruska KL, Lanefeld CD, et al. Relationships between serum MCP-1 and subclinical kidney disease: African American-Diabetes Heart Study. BMC Nephrol 2012;13:148.

73. Poggio E, Rule A, Tanchanco R, Arrigain D, Butler R, Srinivas T, Stephany B, Meyer K, Nurko S, Fatica R, et al. Demographic and clinical characteristics associated with glomerular filtration rates in living kidney donors. Kidney Int 2009;75(10):1079–87.

74. Levey AS, Becker C, Inker L. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. JAMA 2015;313(8):837–46.

75. Rughoooputh MS, Zeng R, Yao Y. Protein diet restriction slows chronic kidney disease progression in non-diabetic and in type 1 diabetic patients, but not in type 2 diabetic patients: a meta-analysis of randomized controlled trials using glomerular filtration rates as a surrogate. PLoS One 2016;10(12):e0145505.

76. Sibbald B. Understanding controlled trials crossover trials. BMJ 1998;316(7146):1719–20.

77. Dangelo G, Potvin D, Turgeon J. Carry-over effects in bioequivalence studies. J Biopharm Stat 2001;11(1-2):35–43.

78. Elbourne D, Altman D, Higgins J, Curtin F, Worthington H, Vail A. Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol 2002;31(1):140–9.

79. WHO: FAO; UN University. Protein and amino acid requirements in human nutrition: report of a joint FAO/WHO/UNU expert consultation. World Health Organ Tech Rep Ser 2007:935, p. 224.

80. Institute of Medicine. Dietary Reference Intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids. Washington (DC): National Academies Press; 2005.

81. Phillips S, Chevalier S, Leidy H. Protein “requirements” beyond the RDA: implications for optimizing health. Appl Physiol Nutr Metab 2016;41(5):565–72.